Disease · MONDO_0043510

brain injury

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. brain injury. Diseases, record MONDO_0043510. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0043510

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: brain injury; Open Targets
Open Targets ID: MONDO_0043510; Open Targets
Other names: injury of brain; Open Targets
MeSH: D001930; MeSH
Highest stage of its drugs: Approval, for 1 of its 74 drugs, from DailyMed; Open Targets

Drugs74

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
BACLOFEN	CHEMBL701	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
EPOETIN ALFA	CHEMBL1201565	Protein	Phase 3	ClinicalTrials.gov	6	6	2	Drugs and targets
TRANEXAMIC ACID	CHEMBL877	Small molecule	Phase 3	ClinicalTrials.gov	5	5	5	Drugs and targets
PROPOFOL	CHEMBL526	Small molecule	Phase 3	ClinicalTrials.gov	4	4	4	Drugs and targets
RONOPTERIN	CHEMBL1230245	Small molecule	Phase 3	ClinicalTrials.gov	3	2	2	Drugs and targets
AMANTADINE	CHEMBL660	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
CITICOLINE	CHEMBL1231700	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
MAGNESIUM SULFATE	CHEMBL3989857	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
NITRIC OXIDE	CHEMBL1200689	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
PROGESTERONE	CHEMBL103	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets

1 to 10 of 74

See all 74 drugs

Targets83

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
GABRA1	GABA-A receptor; anion channel	6	GABA-A receptor; anion channel positive allosteric modulator	Phase 3	https://conductscience.org/library/genes/2554	Drugs and targets
GABRA2	GABA-A receptor; anion channel	6	GABA-A receptor; anion channel positive allosteric modulator	Phase 3	https://conductscience.org/library/genes/2555	Drugs and targets
GABRA3	GABA-A receptor; anion channel	6	GABA-A receptor; anion channel positive allosteric modulator	Phase 3	https://conductscience.org/library/genes/2556	Drugs and targets
GABRA4	GABA-A receptor; anion channel	6	GABA-A receptor; anion channel positive allosteric modulator	Phase 3	https://conductscience.org/library/genes/2557	Drugs and targets
GABRA5	GABA-A receptor; anion channel	6	GABA-A receptor; anion channel positive allosteric modulator	Phase 3	https://conductscience.org/library/genes/2558	Drugs and targets
GABRA6	GABA-A receptor; anion channel	6	GABA-A receptor; anion channel positive allosteric modulator	Phase 3	https://conductscience.org/library/genes/2559	Drugs and targets
GABRB1	GABA-A receptor; anion channel	6	GABA-A receptor; anion channel positive allosteric modulator	Phase 3	https://conductscience.org/library/genes/2560	Drugs and targets
GABRB2	GABA-A receptor; anion channel	6	GABA-A receptor; anion channel positive allosteric modulator	Phase 3	https://conductscience.org/library/genes/2561	Drugs and targets
GABRB3	GABA-A receptor; anion channel	6	GABA-A receptor; anion channel positive allosteric modulator	Phase 3	https://conductscience.org/library/genes/2562	Drugs and targets
GABRD	GABA-A receptor; anion channel	6	GABA-A receptor; anion channel positive allosteric modulator	Phase 3	https://conductscience.org/library/genes/2563	Drugs and targets

1 to 10 of 83

See all 83 targets

Trials98

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 8 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00545662	Study of Citicoline for the Treatment of Traumatic Brain Injury (COBRIT)	Phase 3	1,213	2012-12-19	Traumatic Brain Injury	CITICOLINE	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT01990768	Prehospital Tranexamic Acid Use for Traumatic Brain Injury	Phase 2	967	2019-01-14	Traumatic Brain Injury	TRANEXAMIC ACID	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT00822900	Progesterone for the Treatment of Traumatic Brain Injury III	Phase 3	882	2015-07-03	Traumatic Brain Injury	PROGESTERONE	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT02361944	Risk of Oxygen During Cardiac Surgery Trial	Phase 2/3	213	2023-08-14	Cardiac Surgery	OXYGEN	Its record names the disease	ClinicalTrials.gov
NCT04726410	Cold-stored Platelet Early Intervention in TBI	Phase 2	100	2025-04-29	Traumatic Brain Injury	PLATELETS	Open Targets' reading of its record	ClinicalTrials.gov
NCT01670526	Rivastigmine Patch in Veterans With Cognitive Impairment Following TBI	Phase 3	94	2017-07-25	Traumatic Brain Injury, Cognitive Impairment	RIVASTIGMINE	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT00766038	Recombinant Human Growth Hormone During Rehabilitation From Traumatic Brain Injury.	Phase 2	63	2019-11-18	Traumatic Brain Injury	SOMATROPIN	Open Targets' reading of its record	ClinicalTrials.gov
NCT00973674	Resuscitative Endocrinology:Single-dose Clinical Uses for Estrogen-Traumatic Brain Injury	Phase 2	50	2019-11-12	Traumatic Brain Injury	ESTROGENS, CONJUGATED	Open Targets' reading of its record	ClinicalTrials.gov
NCT01322048	DASH After TBI Study: Decreasing Adrenergic or Sympathetic Hyperactivity After Traumatic Brain Injury	Phase 2	48	2017-06-08	Brain Injuries, Craniocerebral Trauma, Trauma, Nervous System, Traumatic Brain Injury	CLONIDINE, PROPRANOLOL	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT03496545	Efficacy of Bromocriptine For Fever Reduction in Acute Neurologic Injury	Phase 1/2	47	2021-06-24	Subarachnoid Hemorrhage, Subdural Hematoma, Traumatic Brain Injury, Ischemic Stroke, Fever, Intracerebral Hemorrhage	BROMOCRIPTINE	Open Targets' reading of its record	ClinicalTrials.gov

1 to 10 of 98

See all 98 trials

Comparisons in its trials40

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Treatment vs Control: serious adverse events	117 of 607	117 of 606	1,213	NCT00545662	Trial comparisons
Progesterone vs Placebo: serious adverse events	246 of 442	251 of 440	882	NCT00822900	Trial comparisons
Normoxia vs Hyperoxia: Number of People With Arrhythmia	37 of 100	46 of 100	200	NCT02361944	Trial comparisons
Normoxia vs Hyperoxia: Respiratory Failure	5 of 100	1 of 100	200	NCT02361944	Trial comparisons
Normoxia vs Hyperoxia: Acute Brain Dysfunction (Delirium)	16 of 100	22 of 100	200	NCT02361944	Trial comparisons
Normoxia vs Hyperoxia: deaths from any cause	2 of 100	0 of 100	200	NCT02361944	Trial comparisons
Normoxia vs Hyperoxia: Acute Kidney Injury, According to KDIGO Criteria	21 of 100	21 of 100	200	NCT02361944	Trial comparisons
Normoxia vs Hyperoxia: Number of People With Stroke	1 of 100	2 of 100	200	NCT02361944	Trial comparisons
Normoxia vs Hyperoxia: serious adverse events	8 of 100	11 of 100	200	NCT02361944	Trial comparisons
Cold-stored Platelet (CSP) vs Standard Care: Study Feasibility	50 of 50	50 of 50	100	NCT04726410	Trial comparisons

1 to 10 of 40

See all 40 comparisons in its trials

Papers from its trials76

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
41446562	RESULT	1	PubMed
41214784	RESULT	1	PubMed
38885949	RESULT	1	PubMed
37599009	RESULT	1	PubMed
37009524	RESULT	1	PubMed
32664792	RESULT	1	PubMed
32278572	RESULT	1	PubMed
31299040	RESULT	1	PubMed
31271691	RESULT	1	PubMed
31070807	RESULT	1	PubMed

1 to 10 of 76

See all 76 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0043510

GET https://conductscience.org/api/diseases/v1/MONDO_0043510/drugs?page=2

API reference For AI assistants